In their article, AstraZeneca chief-executive Pascal Soriot and biopharmaceuticals-research-and-development executive-vice-president Sir Mene Pangalos say giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”.
